Nexalin shares are trading lower. The company reported exploratory ADAS-Cog data from its completed trial of the Gen-2 SYNC DIFS neurostimulation device in in mild Alzheimer’s disease.

Benzinga Newsdesk www.benzinga.com Negative 59.3%

Neg 59.3% Neu 0% Pos 0%

Comments

No comments yet. Be the first!